SCHEMBL358275

SCHEMBL358275

C[C@@](S)(C(=O)O)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP2C19 P33261 3/20 0.45
HIF1A Q16665 1/20 0.45
CYP1A2 P05177 2/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
CYP2D6 P10635 1/20 0.42
KCNN4 O15554 1/20 0.41
ALDH1A1 P00352 3/20 0.40
ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5524703 1.00 MAPT (0.47) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL6829887 0.77 MAPT (0.50) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL3726386 0.73 CYP1A2 (0.54) MAPTKMT2ACYP2C19HIF1ACYP1A2
Acetic Acid SCHEMBL11528737 0.73 MAPT (0.50) MAPTKMT2ACYP2C19HIF1ACYP1A2
Ethane SCHEMBL14127500 0.73 CYP1A2 (0.48) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL112992 0.72 CYP1A2 (0.52) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL31276141 0.72 CYP1A2 (0.52) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL4592372 0.72 CYP1A2 (0.52) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL1560417 0.72 MAPT (0.54) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL73063 0.72 HDAC3 (0.61) MAPTKMT2ACYP2C19HIF1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780935-B2 Mutant antibodies and conjugation thereof PFIZER HEALTHCARE IRELAND (IE) 2023-10-10 US disclosed
CN-116333053-A Atosiban and method for inhibiting formation of polymeric impurities 海南中和药业股份有限公司 2023-06-27 CN disclosed
US-20220273664-A1 Mitochondrial Targeted Releasable Linker THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-09-01 US disclosed
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF PFIZER HEALTHCARE IRELAND (IE) 2021-05-20 US disclosed
EP-3395358-B1 INSULIN ANALOG DIMERS UNIV INDIANA RES & TECH CORP (US) 2019-11-06 EP disclosed
EP-2900255-B1 INSULIN ANALOG DIMERS UNIV INDIANA RES & TECH CORP (US) 2019-01-30 EP disclosed
WO-2018232491-A1 MITOCHONDRIAL TARGETED RELEASABLE LINKER THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2018-12-27 WO disclosed
EP-3395358-A1 INSULIN ANALOG DIMERS Indiana University Research and Technology Corporation (US) 2018-10-31 EP disclosed
EP-2593142-B1 MULTIFUNCTIONAL ANTIBODY CONJUGATES COVX TECH IRELAND LIMITED (IE) 2018-10-10 EP disclosed
EP-2802355-B1 MUTANT ANTIBODIES AND CONJUGATION THEREOF COVX TECH IRELAND LIMITED (IE) 2018-09-05 EP disclosed
US-7869958-B2 Structure-based modulators of B1 G-protein coupled receptors RESEARCH DEVELOPMENT FOUNDATION (US) 2011-01-11 US disclosed
EP-2164519-A2 LONG-ACTING POLYMERIC PRODRUGS OF EXENDIN Ascendis Pharma AS (DK) 2010-03-24 EP disclosed
WO-2008148839-A2 LONG-ACTING POLYMERIC PRODRUGS OF EXENDIN ASCENDIS PHARMA AS (DK) 2008-12-11 WO disclosed
US-7312195-B2 Cyclised conotoxin peptides THE UNIVERSITY OF QUEENSLAND (AU) 2007-12-25 US disclosed
US-20060069516-A1 Structure-based modulators of B1 G-protein coupled receptors RESEARCH DEVELOPMENT FOUNDATION (US) 2006-03-30 US disclosed
WO-2006031322-A2 DETERMINATION OF THE 3D-STRUCTURE OF AN EXTRACELLULAR DOMAIN OF A B1 G-PROTEIN COUPLED RECEPTOR BY NMR ANALYSIS RESEARCH DEVELOPMENT FOUNDATION (US) 2006-03-23 WO disclosed
US-20050256301-A1 Cyclised conotoxin peptides THE UNIVERSITY OF QUEENSLAND (AU) 2005-11-17 US disclosed
EP-0013261-B1 GUAIACOL ESTERS OF ALPHA- AND BETA-MERCAPTOPROPIONYLALANINE AND ALPHA- AND BETA-MERCAPTOPROPIONYLGLYCINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1982-12-01 EP disclosed
US-4299842-A TREATMENT OF RESPIRATORY SYSTEM DISORDERS, NUCOLYTIC AGENTS CAVAZZA CLAUDIO 1981-11-10 US disclosed
EP-0013261-A1 Guaiacol esters of alpha- and beta-mercaptopropionylalanine and alpha- and beta-mercaptopropionylglycine, process for their preparation and pharmaceutical compositions containing same Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1980-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147576-A1 MUTANT ANTIBODIES AND CONJUGATION THEREOF IGLV6-57, IGSF11, F13B MAPT 114/4885KMT2A 1718/4885CYP2C19 4260/4885
US-20050256301-A1 Cyclised conotoxin peptides VIP, CANX, IAPP MAPT 1962/4885KMT2A 4153/4885CYP2C19 2581/4885
US-11780935-B2 Mutant antibodies and conjugation thereof IGLV6-57, IGSF11, F13B MAPT 104/4885KMT2A 1715/4885CYP2C19 4254/4885
US-20220273664-A1 Mitochondrial Targeted Releasable Linker PDF, NDUFAB1, AURKAIP1 MAPT 1202/4885KMT2A 3845/4885CYP2C19 2837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.